Oncoscope Officially Launches, Ushering in a New Era of Real-Time Oncology Intelligence
Oncoscope officially launches, offering real-time, powered by AI, oncology insights to doctors. Free for verified clinicians, it helps improve cancer treatment decisions in just three clicks. Oncoscope-AI, a revolutionary oncology intelligence platform, has officially launched following a successful beta phase and over a year of strategic development that involved extensive conversations with practicing oncologists. The platform, which delivers real-time, human-curated cancer insights enhanced by artificial intelligence, is now live and available free of charge to verified healthcare professionals worldwide. Founded by Anna Forsythe, a pharmacist, health economist, and seasoned pharmaceutical executive, Oncoscope addresses a critical gap in oncology care. It gives clinicians instant access to the most current treatment data, FDA approvals, and guideline-aligned information, consolidated into one user-friendly platform. “Doctors do not need more data. They need the right information, at the right time, in a format they can use to make better decisions for their patients,” said Forsythe. “Oncoscope provides that clarity. It is a living library of oncology, curated by experts and built to save lives.” Unlike generic AI tools or static databases, Oncoscope uses trained AI to scan thousands of oncology publications and filters them through a rigorous, evidence-based framework. Each entry is cross-referenced with clinical guidelines and regulatory approvals to ensure usability and relevance. All of the results are carefully scrutinized by a team of experienced researchers. Currently, the platform supports breast and lung cancer, with prostate, bladder, colon, and rectal modules rolling out in the coming months. The process is intuitive. Physicians answer three clinical questions—cancer stage, genetic markers, and prior treatments—and receive a personalized, actionable summary. Each recommended article includes survival data, progression insights, treatment efficacy, and toxicity, extracted across 32 key clinical parameters. “The result is something physicians can actually use in the moment,” said Forsythe. “It takes three clicks to go from a patient in the room to the most up-to-date evidence in the field.” Access to Oncoscope is free for verified healthcare professionals, including physicians, nurses, pharmacists, genetic counselors, and physician assistants. Non-verified users, such as those in finance or consulting, can purchase limited access at a monthly rate, restricted to a single cancer type. This structure reflects the company’s commitment to empowering front-line clinicians with better tools—without barriers. Forsythe, who previously founded and sold a successful health economics company serving global pharmaceutical clients, brings a rare combination of clinical, technical, and business expertise to this venture. She sees Oncoscope not only as a tool, but as a mission. “This platform was born from both professional insight and personal urgency,” she said. “Too many patients are still receiving outdated treatments, simply because their doctors do not have time to stay current. I realized I had the knowledge, the team, and the experience to fix that.” With a lean team, strategic vision, and a rapidly growing user base, Oncoscope is poised to become a trusted global resource in cancer treatment.“We are not just a tech company,” said Forsythe. “We are part of the oncology ecosystem. And we are here to help doctors deliver the best care possible.” Beka Vinogradov is the Digital Communications Lead for Oncoscope-AI. She holds a Master’s in Health Administration and has extensive experience and education in business, marketing, and design.
Founder Spotlight: Anna Forsythe, PharmD — Bringing Clarity to the Chaotic and Rapid Data Influx in Oncology with Oncoscope AI
As seen in Oncologist Daily, ASCO 2025 Edition The pace of progress in oncology is both exhilarating and overwhelming. New clinical trials, biomarkers, FDA approvals, and updated guidelines appear almost daily, creating a deluge of information that even the most diligent oncologists struggle to absorb. For Anna Forsythe, who had lost two good friends to cancer — and who is trying to help a third with a difficult diagnosis — this was more than just a challenge. It was a call to action. As the founder of Oncoscope AI, Anna has set out to build what she calls “a GPS for oncology.” Much like a car navigation system that recalculates routes in real time based on constantly changing traffic patterns, Oncoscope AI continuously updates to reflect the latest evidence — synthesizing and collating research data, treatment guidelines and regulatory approvals into a single, streamlined view designed for oncologists to use in real time at the point of care. “Oncoscope doesn’t replace the physician’s judgment,” Forsythe explains. “It augments it — giving clinicians a clear, current, and unbiased and easy to use view of what’s changing in real time, so they can spend less time digging through papers and more time with their patients.” This balance of innovation and practicality reflects Anna’s own background. A clinically trained Doctor of Pharmacy, she holds a Master’s Degree in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. Her career spans both the clinical and strategic sides of the pharmaceutical industry — with leadership in both oncology and non-oncology roles roles in global value and access at Eisai Co., and earlier positions at Novartis and Bayer in clinical research and health economics. She’s no stranger to entrepreneurship either. Anna previously co-founded Purple Squirrel Economics, a health economics consultancy that was acquired by Cytel, the Cambridge, Massachusetts-based statistical software developer and contract research organization, in 2020. Her work has appeared in leading journals and conference podiums alike, including a top-ranked JAMA Pediatrics article, which placed in the top 5 percent of all JAMA research outputs worldwide. But it’s Oncoscope that brings her experiences full circle — combining clinical insight, economic acumen, and a passion for scalable solutions that work in real-world oncology settings. As thousands of oncologists gather at ASCO 2025 to digest the latest data and translate it into better care, Oncoscope AI offers a timely reminder that innovation doesn’t have to be overwhelming — if it’s built from the ground up with the physician in mind. “We’re not a technology in search of an application — and we’re not at all suggesting that oncologists change how they practice,” says Forsythe. “They are the experts. We are merely helping them by building a tool that fits seamlessly into their reality — one that helps them keep up with the latest information, and communicate the most up-to-date strategies clearly with patients. The goal is to help them stay focused on what matters most: delivering the best possible care.” With Oncoscope AI, Anna Forsythe is leading a new kind of precision oncology — one where evidence and empathy meet at the bedside, powered by smart, real-time technology. Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied. A clinically trained Doctor of Pharmacy (PharmD), Anna also holds a Master’s in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. She previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020) and led Global Value and Access at Eisai Pharmaceuticals, following earlier roles at Novartis and Bayer in clinical research and health economics.
Saving Lives in Real Time: Why Oncology Must Embrace AI, but Carefully
In January, my close friend Susan received devastating news: after six long years of navigating chemotherapy, surgery, radiation, and a targeted therapy that had finally given her back her quality of life, her breast cancer had returned, this time to her liver. She was terrified, not just of the disease, but of what might come next. “I just don’t want to go through chemo again,” she said, fighting back tears. “Is there anything new?” Her oncologist, she said, was excellent. But like so many today, he was overwhelmed. She feared he wouldn’t have time to search for new options that might have emerged in recent months. As a health economist, I’ve spent years sifting through research and data, and I knew that finding up-to-date, reliable information shouldn’t depend on how many hours a doctor can spare after a crushing workload serving patients in the clinic. The mountain of data is overwhelming to even the most dedicated physician trying to keep up. In 2024 alone, over 4,800 papers were published describing breast cancer clinical trials. In the first three months of 2025, another 860 have already appeared. Meanwhile, headlines everywhere tout artificial intelligence (AI) as a revolutionary force in healthcare. But wise physicians and patients alike know the truth: while AI’s potential is enormous, its safe and meaningful application demands careful human oversight, clinical rigor, and a deep understanding of what is at stake. That’s why I turned to a new kind of tool—an AI system specifically designed for medicine, rigorously vetted by human experts, and built not just to gather data, but to curate it, critically evaluate it, and prioritize clinical relevance. Far beyond your average ChatGPT-style chatbot, the tool was a hybrid system: part artificial intelligence, part human expertise. Behind the scenes, it performed a systematic review of the latest literature, flagged high-quality clinical trials, and filtered out unreliable data, creating a curated, searchable database of real, actionable evidence. Within minutes, this hybrid AI-human platform helped me discover a promising new class of drugs—antibody-drug conjugates or ADCs. These therapies target chemotherapy precisely to cancer cells, sparing healthy tissue and potentially reducing side effects. One ADC had just demonstrated outstanding results in a major clinical trial—results so recent they hadn’t yet made it into official treatment guidelines. Susan shared this information with her oncologist. After reviewing the evidence, he agreed. Today, she is on the new therapy—and planning her next vacation. As Dr. Mehran Habibi, a leading breast cancer surgical oncologist in New York, put it to me recently: “AI can’t replace clinical judgment—but it can support it. The only way physicians will trust these tools is if they know the science behind them has been vetted by humans who understand the stakes.” What’s striking isn’t just the speed with which this information was uncovered, but the fact that it could so easily have been missed, he said. “While oncologists are expected to stay on top of a constantly evolving field, the guidelines they depend on, produced by expert committees, are updated infrequently, and, despite the best of intentions, are not immune to biases or conflicts of interest. Additionally, tools like ChatGPT, while popular, can’t be trusted to provide rigorously sourced, clinically relevant information. They’re prone to consider misinformation and half-truths rampant on the internet, and often present content that is incomplete, outdated, or based on opinion rather than evidence.” ChatGPT and other apps that utilize AI are powerful tools in many fields, but not necessarily for clinical science, which demands the highest rigorous standards to be useful to oncologists, he continued. “We don’t rely on GPS apps that guess which roads exist — we expect accuracy and live updates. We don’t book flights through websites that suggest destinations based on personal blogs instead of real availability. So why would we accept anything less in cancer care?” The future of oncology demands “living guidelines”—dynamic, continuously updated frameworks that reflect the latest discoveries, not just a data-dump collected over the last 12 months. That’s what this new class of AI/human tools can enable. They don’t replace the physician. They equip them. And that’s the real power of this approach: it can free up doctors to spend more time with their patients, not less. AI/human tools can support medical education, help residents prepare for board exams, and enhance shared decision-making by providing clear, visual explanations of treatment paths. Susan’s story has a hopeful turn. But there are countless others who may not be as lucky unless we rethink how we connect patients to the best and latest therapies. The race between cancer and medicine is relentless. It’s time we give our doctors the tools to win it. Not because they make decisions for us, but because they make it easier to find the right ones. Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied. A clinically trained Doctor of Pharmacy (PharmD), Anna also holds a Master’s in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. She previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020) and led Global Value and Access at Eisai Pharmaceuticals, following earlier roles at Novartis and Bayer in clinical research and health economics.
Clinicians Don’t Need More Data, They Need Usable Insights
In oncology, where time is critical and treatment paths are complex, clear and timely communication with patients isn’t a “nice to have,” it’s essential. In this short video, Chad Levitt highlights a core challenge in cancer care: when oncologists have to spend valuable time interpreting dense data, it delays the clarity patients need. The reality is, clinicians aren’t just looking for more information; they’re looking for usable information. Tools like Oncoscope-AI are designed with this in mind, delivering real-time oncology data that’s already filtered, prioritized, and clinically relevant. That means faster decision-making, clearer communication with patients, and a better care experience at one of the most critical moments in someone’s life. Because when we streamline the way doctors access and interpret clinical evidence, we ultimately serve the person who matters most: the patient. Beka Vinogradov is the Digital Communications Lead for Oncoscope-AI. She holds a Master’s in Health Administration and has extensive experience and education in business, marketing, and design.
From Information Overload to Meaningful Insight: Helping Oncologists Make Confident Treatment Decision
In today’s fast-paced oncology environment, physicians are tasked with making complex treatment decisions while navigating an ever-expanding body of clinical data. As Dr. Jessicca Rege shares in the video, the challenge isn’t access to information, it’s finding information that’s useful, relevant, and aligned with a specific patient’s clinical context. Every week brings new trial results, updated guidelines, and shifting regulatory approvals. For oncologists managing dozens of patient cases, keeping up isn’t just time-consuming, it’s nearly impossible without the right tools. That’s where Oncoscope-AI steps in. Built for the real-world demands of cancer care, our platform transforms data into real-time, patient-specific insights. By combining the speed of AI with the clinical rigor of expert human review, we help oncology teams focus on what matters: making confident, evidence-based decisions at the point of care. The future of cancer treatment isn’t just about more data, it’s about meaningful data. And it’s about time clinicians had the support they need to cut through the noise and focus on what drives outcomes. Beka Vinogradov is the Digital Communications Lead for Oncoscope-AI. She holds a Master’s in Health Administration and has extensive experience and education in business, marketing, and design.
Why Oncologists Need More Than Guidelines, They Need Living Intelligence
Clinical guidelines are an essential foundation in oncology, but they’re not enough. As Dr. Jessicca Rege highlights in the video, by the time guidelines are published, they often lag behind the most current clinical trial results, emerging biomarkers, and FDA approvals. In a field evolving as quickly as oncology, even the best guidelines can feel outdated the moment they’re released. What oncologists need isn’t just a static reference point, they need living, adaptive tools that evolve in real time. That’s the power of Oncoscope-AI, a platform that bridges the gap between traditional guidelines and cutting-edge clinical intelligence. It continuously ingests and synthesizes the latest trial data, guideline updates, and regulatory changes, then applies expert human review to ensure clinical relevance. The result? A dynamic, reliable source of information that keeps up with the pace of oncology and with the needs of every patient. When treatment decisions can’t wait, Oncoscope-AI gives you the latest data so you’re never relying on yesterday’s evidence. Beka Vinogradov is the Digital Communications Lead for Oncoscope-AI. She holds a Master’s in Health Administration and has extensive experience and education in business, marketing, and design.
A New Approach for Oncology Decision Support
In oncology, change doesn’t wait. Clinical trial data evolves by the hour, guidelines shift rapidly, and regulatory approvals are updated in real time. For practicing oncologists seeing 20–30 patients a day, staying “up to date” often feels like an impossible task. Traditional tools simply weren’t built for the speed or complexity of modern cancer care. As Dr. Sarkisian shares in his recent discussion, the challenge isn’t just access to information, it’s access to the right information, when it matters. Sifting through endless trial abstracts, publications, and guidelines leaves little room for practical, real-time decision-making. And the cost of delay isn’t theoretical, it impacts lives. That’s where Oncoscope-AI comes in. By combining the speed of AI with the clinical judgment of expert human reviewers, Oncoscope-AI filters, organizes, and prioritizes the most relevant oncology data daily. It’s not just another search tool or chatbot. It’s a decision support platform purpose-built to meet oncologists where they are: at the point of care, under pressure, and in need of trusted, clinically aligned information. In less than three clicks, physicians can access: Physicians know, real-time decisions demand real-time data; anything less puts patients at risk. Beka Vinogradov is the Digital Communications Lead for Oncoscope-AI. She holds a Master’s in Health Administration and has extensive experience and education in business, marketing, and design.
Real-World Relevance: Dr. Chad Levitt on AI That Works for Doctors
What does meaningful innovation look like in oncology? Dr. Chad Levitt believes it’s not just about new technology, it’s about how we use it. In this video, he shares a clinician’s perspective on what makes AI valuable at the point of care: relevance, clarity, and trust. With clinical teams already overwhelmed by fragmented, constantly evolving oncology data, what they don’t need is more information. What they do need is the right information. And they need it delivered in a way that fits their clinical workflows and supports real-time treatment decisions. That’s the vision behind Oncoscope-AI, a hybrid platform that combines the speed of artificial intelligence with the insight of expert human review. It’s designed specifically for oncology teams, not just to summarize data, but to organize, interpret, and prioritize it with clinical nuance. Dr. Levitt’s message is clear, Tools like Oncoscope aren’t here to replace clinicians. They’re here to support them in doing what they do best, making confident, evidence-based decisions for their patients. “We don’t need more noise. We need intelligent filtering. That’s what makes AI useful in practice, not just possible in theory.” – Dr. Chad Levitt Beka Vinogradov is the Digital Communications Lead for Oncoscope-AI. She holds a Master’s in Health Administration and has extensive experience and education in business, marketing, and design.